...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril.
【24h】

Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril.

机译:通过血管紧张素转化酶抑制剂卡托普利的早期治疗,自发性高血压大鼠肾脏血管紧张素II受体的变化。

获取原文
           

摘要

We tested the hypothesis that in utero treatment with the angiotensin-converting enzyme inhibitor captopril could change the affinity, density, and/or subtypes of angiotensin II (Ang II) receptors in the kidneys of spontaneously hypertensive rats (SHR). Newborn, 7-day-old, and 4-month-old SHR and Wistar-Kyoto (WKY) rats were used. SHR and WKY rat breeders were treated with captopril (0.4 mg/mL, 100 mg/kg per day) in drinking water, and their pups were maintained on captopril treatment until experimentation. Control groups were untreated, age-matched SHR and WKY rats. The density, affinity, and subtypes of renal Ang II receptors were determined using radioligand binding techniques and receptor antagonists specific for Ang II receptor subtypes 1 and 2 (losartan, an AT1-specific antagonist, and CGP 42112B, an AT2-specific antagonist). AT1 receptor density in kidneys was higher than AT2 receptor density in both neonatal and adult rats. AT1 receptor density in kidneys increased approximately twofold from birth to 7 days of age in all groups. Newborn and 7-day-old SHR showed significantly greater Ang II receptor densities in kidneys than other rat groups because of significantly greater densities of both AT1 and AT2 receptors. At 4 months of age, there were no significant differences in Ang II receptor densities in kidneys between captopril-treated and control SHR. Our data indicate that the expression of AT1 and AT2 receptors in kidneys is differentially regulated during development. Enhanced activity of the renal renin-Ang II system in newborn and probably fetal SHR may be involved in the pathogenesis of hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)
机译:我们测试了以下假设,即在子宫内使用血管紧张素转换酶抑制剂卡托普利治疗可改变自发性高血压大鼠(SHR)肾脏中血管紧张素II(Ang II)受体的亲和力,密度和/或亚型。使用新生,7天和4个月大的SHR和Wistar-Kyoto(WKY)大鼠。 SHR和WKY大鼠饲养员在饮用水中用卡托普利(0.4 mg / mL,每天100 mg / kg)进行处理,并将它们的幼崽维持在卡托普利治疗之前,直到进行实验。对照组为未治疗,年龄匹配的SHR和WKY大鼠。使用放射性配体结合技术和对Ang II受体亚型1和2特异的受体拮抗剂(氯沙坦(AT1特异性拮抗剂)和CGP 42112B(AT2特异性拮抗剂))确定肾脏Ang II受体的密度,亲和力和亚型。在新生大鼠和成年大鼠中,肾脏的AT1受体密度均高于AT2受体密度。在所有组中,从出生到7天龄,肾脏中的AT1受体密度大约增加了两倍。新生和7天大的SHR在肾脏中显示的Ang II受体密度明显高于其他大鼠组,这是因为AT1和AT2受体的密度都明显更高。在4个月大时,卡托普利治疗组和对照组SHR之间肾脏的Ang II受体密度没有显着差异。我们的数据表明,AT1和AT2受体在肾脏中的表达在发育过程中受到差异调节。新生儿和可能是胎儿SHR的肾素-Ang II系统活性增强可能与高血压的发病机理有关(摘要截断为250字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号